ArticleAntimicrobial agents and chemotherapy2019
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.Journal of women's health (2002) · 2023Trial
- Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).BJOG : an international journal of obstetrics and gynaecology · 2022Trial
- Elevated in vitro activity of ibrexafungerp against azole-resistant Candida isolates from Vulvovaginal Candidiasis (VVC): a multicentric study from India.Archives of microbiology · 2026Article
- Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2025Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Ibrexafungerp: A narrative overview.Current research in microbial sciences · 2024Review
- Headaches in a Horseback Rider.Open forum infectious diseases · 2023Article
- Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.Drug design, development and therapy · 2023Review
- Antifungal resistance, combinations and pipeline: oh my!Drugs in context · 2023Review
- New Approaches to Manage Infections in Transplant Recipients: Report From the 2023 GTI (Infection and Transplantation Group) Annual Meeting.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.Journal of fungi (Basel, Switzerland) · 2022Review
- The Menace ofDiseases (Basel, Switzerland) · 2022Review
- Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.Expert opinion on investigational drugs · 2022Article
- Impact ofAntimicrobial agents and chemotherapy · 2022Article
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.Drugs · 2021Review
- Article
- Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.Journal of fungi (Basel, Switzerland) · 2021Review
- Novel antifungal agents in clinical trials.F1000Research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SCY-078, a fungicidal β-1,3-glucan synthesis inhibitor administered as intravenous or oral [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.